iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

USFDA issues 10 observations after inspection of Lupin manufacturing facility

31 Mar 2023 , 09:37 AM

Lupin announced on Thursday that its manufacturing facility in Pithampur Unit-2 was inspected by the US Food and Drug Administration (USFDA) from March 21 to March 29, 2023. As a result of the inspection, the USFDA issued a Form-483 containing ten observations.

Lupin stated in a regulatory filing that following the inspection, the issuance of a Form-483 with ten observations concluded the process.

The company also stated that it is taking comprehensive measures to address the observations and will collaborate with the USFDA to resolve the issues as soon as possible.

Following an inspection, the United States Food and Drug Administration (FDA) issues a Form 483 to the management of a company if any observations are made that suggest the presence of conditions that may be deemed violative of the Food Drug and Cosmetic (FD&C) Act and its associated legislation.

Lupin’s Mandideep-based manufacturing facility received a Form-483 with eight observations each for its product and raw material production centers from the USFDA in November of last year.

At around 9.36 AM, Lupin was trading 1.79% lower at Rs641.20, against the previous close of Rs652.40 on NSE. The counter opened at Rs644.65.

For feedback and suggestions, write to us at editorial@iifl.com

explored-media

Related Tags

  • Form 483
  • Lupin
  • Lupin News
  • Lupin Updates
  • Lupin USFDA
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.